228 related articles for article (PubMed ID: 17325342)
41. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
[TBL] [Abstract][Full Text] [Related]
42. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
43. [Combined gene therapy for murine liver cancer with interleukin-18 and cytosine deaminase genes].
Sun W; Tang Z; Wei D; Tang Y; Chen S
Zhonghua Gan Zang Bing Za Zhi; 2001 Oct; 9(5):300-2. PubMed ID: 11676879
[TBL] [Abstract][Full Text] [Related]
44. Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity.
Wan YL; Zheng SS; Zhao ZC; Li MW; Jia CK; Zhang H
World J Gastroenterol; 2004 Jan; 10(2):195-9. PubMed ID: 14716821
[TBL] [Abstract][Full Text] [Related]
45. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
[TBL] [Abstract][Full Text] [Related]
46. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
[TBL] [Abstract][Full Text] [Related]
47. Antitumor effect of immunization with fusion of dendritic cells and hepatocellular carcinoma cells in mice.
Zhang H; Zheng SS; Jiang GP; Wu LH; Zhu F; Yang ZL
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):235-40. PubMed ID: 15138117
[TBL] [Abstract][Full Text] [Related]
48. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.
Yoshida H; Katayose Y; Unno M; Suzuki M; Kodama H; Takemura S; Asano R; Hayashi H; Yamamoto K; Matsuno S; Kudo T
Cancer Immunol Immunother; 2003 Feb; 52(2):97-106. PubMed ID: 12594573
[TBL] [Abstract][Full Text] [Related]
49. [Soluble PD-1 can augment anti-tumor immunity induced by HSP70-peptide complex in tumor-bearing mice].
Wang XH; Zhang GM; He YF; Zhang H; Feng ZH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov; 20(6):655-8. PubMed ID: 15555427
[TBL] [Abstract][Full Text] [Related]
50. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
[TBL] [Abstract][Full Text] [Related]
51. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
[TBL] [Abstract][Full Text] [Related]
52. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
53. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
54. Dendritic cells loaded with ultrasound-ablated tumour induce in vivo specific antitumour immune responses.
Deng J; Zhang Y; Feng J; Wu F
Ultrasound Med Biol; 2010 Mar; 36(3):441-8. PubMed ID: 20172447
[TBL] [Abstract][Full Text] [Related]
55. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
Shindo Y; Yoshimura K; Kuramasu A; Watanabe Y; Ito H; Kondo T; Oga A; Ito H; Yoshino S; Hazama S; Tamada K; Yagita H; Oka M
Anticancer Res; 2015 Jan; 35(1):129-36. PubMed ID: 25550543
[TBL] [Abstract][Full Text] [Related]
56. Antitumor and immunomodulatory activity of Astragalus membranaceus polysaccharides in H22 tumor-bearing mice.
Yang B; Xiao B; Sun T
Int J Biol Macromol; 2013 Nov; 62():287-90. PubMed ID: 24060282
[TBL] [Abstract][Full Text] [Related]
57. A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: implication for immunotherapy of human hepatocellular carcinoma.
Atarashi Y; Yasumura S; Nambu S; Yoshio Y; Murakami J; Takahara T; Higuchi K; Watanabe A; Miyata K; Kato M
Hepatology; 1998 Jul; 28(1):57-67. PubMed ID: 9657097
[TBL] [Abstract][Full Text] [Related]
58. Specific cellular immune response elicited by the necrotic tumor cell-stimulated macrophages.
Yuan X; Li W; Cui Y; Zhan Q; Zhang C; Yang Z; Li X; Li S; Guan Q; Sun X
Int Immunopharmacol; 2015 Jul; 27(1):171-6. PubMed ID: 25981111
[TBL] [Abstract][Full Text] [Related]
59. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.
Fatourou EM; Koskinas JS
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1499-510. PubMed ID: 19828011
[TBL] [Abstract][Full Text] [Related]
60. [Prostate cancer cell vaccine transfected with 4-1BBL induces anti-tumor immunity in vitro].
Kuang YL; Weng XD; Liu XH; Chen ZY; Zhu HC; Jiang BT
Zhonghua Nan Ke Xue; 2010 Sep; 16(9):773-7. PubMed ID: 21171257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
